GB1495159A - Process reducing the anticomplementary activity of gamma globulins - Google Patents

Process reducing the anticomplementary activity of gamma globulins

Info

Publication number
GB1495159A
GB1495159A GB53020/75A GB5302075A GB1495159A GB 1495159 A GB1495159 A GB 1495159A GB 53020/75 A GB53020/75 A GB 53020/75A GB 5302075 A GB5302075 A GB 5302075A GB 1495159 A GB1495159 A GB 1495159A
Authority
GB
United Kingdom
Prior art keywords
gamma globulin
solution
centrifuged
precipitated
hydroxyethyl starch
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
GB53020/75A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Plasmesco AG
Original Assignee
Plasmesco AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Plasmesco AG filed Critical Plasmesco AG
Publication of GB1495159A publication Critical patent/GB1495159A/en
Expired legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)

Abstract

1495159 Gamma globulin PLASMESCO AG 29 Dec 1975 [2 Jan 1975] 53020/75 Heading A5B [Also in Division C3] The compatability of gamma globulin precipitated from blood or blood products is improved by dissolving the precipitated gamma globulin in an aqueous solution containing from 1 to 30% of a hydroxyethyl starch having a molecular weight of 1000 to 900000 and thereafter recovering the gamma globulin from this solution. In an example gamma globulin precipitate is dissolved in a buffered aqueous solution at pH 6.7 in a concentration of about 6%. About 10% of hydroxyethyl starch (M.W. 1000 to 900000) is added to this solution which facilitates separation of existing gamma globulin aggregates and simultaneously protects non-aggregated gamma globulin molecules. After addition of 10% of polyethyleneglycol the mixture is centrifuged. The remaining supernatant phase is mixed with 20% polyethylene glycol at pH 7.2 and centrifuged. The resulting precipitate is taken up in saline solution and is suitable for the therapeutic use.
GB53020/75A 1975-01-02 1975-12-29 Process reducing the anticomplementary activity of gamma globulins Expired GB1495159A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE2500076A DE2500076C3 (en) 1975-01-02 1975-01-02 Process for the production of intravenously tolerated gamma globulins

Publications (1)

Publication Number Publication Date
GB1495159A true GB1495159A (en) 1977-12-14

Family

ID=5935911

Family Applications (1)

Application Number Title Priority Date Filing Date
GB53020/75A Expired GB1495159A (en) 1975-01-02 1975-12-29 Process reducing the anticomplementary activity of gamma globulins

Country Status (20)

Country Link
JP (1) JPS5512001B2 (en)
AT (1) AT344883B (en)
AU (1) AU505416B2 (en)
BE (1) BE837211A (en)
CA (1) CA1058075A (en)
DD (1) DD121875A5 (en)
DE (1) DE2500076C3 (en)
DK (1) DK144679C (en)
EG (1) EG11987A (en)
ES (1) ES443982A1 (en)
FR (1) FR2296429A1 (en)
GB (1) GB1495159A (en)
IE (1) IE43449B1 (en)
IL (1) IL48766A (en)
IN (1) IN143525B (en)
NL (1) NL179824C (en)
PL (1) PL99599B1 (en)
SE (1) SE437470B (en)
SU (1) SU576898A3 (en)
ZA (1) ZA758050B (en)

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1980002374A1 (en) * 1979-05-10 1980-11-13 American Hospital Supply Corp Hydroxyalkyl starch drug carrier
EP0073371A2 (en) * 1981-08-24 1983-03-09 Miles Laboratories, Inc. Intravenously injectable immune serum globulin and method of preparing same
EP1190719A1 (en) * 2000-08-17 2002-03-27 B. Braun Melsungen Ag Colloidal pharmacomodulation of injected pharmaceutical compositions
US8497072B2 (en) 2005-11-30 2013-07-30 Abbott Laboratories Amyloid-beta globulomer antibodies
US8691224B2 (en) 2005-11-30 2014-04-08 Abbvie Inc. Anti-Aβ globulomer 5F7 antibodies
US8877190B2 (en) 2006-11-30 2014-11-04 Abbvie Inc. Aβ conformer selective anti-Aβ globulomer monoclonal antibodies
US8895004B2 (en) 2007-02-27 2014-11-25 AbbVie Deutschland GmbH & Co. KG Method for the treatment of amyloidoses
US8987419B2 (en) 2010-04-15 2015-03-24 AbbVie Deutschland GmbH & Co. KG Amyloid-beta binding proteins
US9062101B2 (en) 2010-08-14 2015-06-23 AbbVie Deutschland GmbH & Co. KG Amyloid-beta binding proteins
US9176150B2 (en) 2003-01-31 2015-11-03 AbbVie Deutschland GmbH & Co. KG Amyloid beta(1-42) oligomers, derivatives thereof and antibodies thereto, methods of preparation thereof and use thereof

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2604759C2 (en) * 1976-02-07 1983-06-01 SCHURA Blutderivate GmbH & Co KG, 4150 Krefeld Method of Obtaining IV Compatible Gamma Globulins
JPS6016406B2 (en) * 1976-08-06 1985-04-25 マイヤ−、ル−イス、コ−バル Method for producing intravenously administrable gamma globulin and gamma globulin prepared thereby
US4124576A (en) * 1976-12-03 1978-11-07 Coval M L Method of producing intravenously injectable gamma globulin
GB1603244A (en) * 1977-05-20 1981-11-18 Max Planck Gesellschaft Medicaments for the suppression of pathological processes
JPS5822085B2 (en) * 1977-07-19 1983-05-06 株式会社ミドリ十字 Intravenous gamma globulin preparations
AT359641B (en) * 1978-09-19 1980-11-25 Immuno Ag METHOD FOR PRODUCING AN INTRAVENOUS ADMINISTRABLE ANTIBODY-CONTAINING IMMUNOGLOBULIN PREPARATE
EP0085747B2 (en) * 1982-02-08 1990-05-30 Schweizerisches Serum- und Impfinstitut und Institut zur Erforschung der Infektionskrankheiten Intravenously administrable human immunoglobuline and process for its preparation
US4482483A (en) * 1983-04-06 1984-11-13 Armour Pharmceutical Company Composition of intravenous immune globulin
SE8302483L (en) * 1983-05-02 1984-11-03 Pharmacia Ind PROCEDURE FOR PURIFICATION OF BIOLOGICALLY ACTIVE SUBSTANCES
US5945098A (en) * 1990-02-01 1999-08-31 Baxter International Inc. Stable intravenously-administrable immune globulin preparation
DE19907257A1 (en) * 1999-02-21 2000-09-14 Bernd Horst Meier Means for controlling the diffusion of injection solutions

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE348942B (en) * 1970-06-02 1972-09-18 Statens Bakteriologiska Labor
DE2234069A1 (en) * 1971-07-16 1973-02-08 South African Inventions METHOD OF MANUFACTURING A PURIFIED GAMMA GLOBULIN
ZA738779B (en) * 1972-11-27 1974-10-30 Baxter Laboratories Inc Production of gamma globulin
JPS49101516A (en) * 1973-01-13 1974-09-25

Cited By (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1980002374A1 (en) * 1979-05-10 1980-11-13 American Hospital Supply Corp Hydroxyalkyl starch drug carrier
EP0028641A1 (en) * 1979-05-10 1981-05-20 American Hospital Supply Corp Hydroxyalkyl starch drug carrier.
EP0028641A4 (en) * 1979-05-10 1981-09-01 American Hospital Supply Corp Hydroxyalkyl starch drug carrier.
EP0019403A3 (en) * 1979-05-10 1981-10-07 American Hospital Supply Corporation Hydroxyalkyl-starch drug carrier and method of administering a biologically active compound to an animal
EP0073371A2 (en) * 1981-08-24 1983-03-09 Miles Laboratories, Inc. Intravenously injectable immune serum globulin and method of preparing same
EP0073371A3 (en) * 1981-08-24 1983-09-21 Miles Laboratories Inc. Intravenously injectable immune serum globulin and method of preparing same
EP1190719A1 (en) * 2000-08-17 2002-03-27 B. Braun Melsungen Ag Colloidal pharmacomodulation of injected pharmaceutical compositions
US10464976B2 (en) 2003-01-31 2019-11-05 AbbVie Deutschland GmbH & Co. KG Amyloid β(1-42) oligomers, derivatives thereof and antibodies thereto, methods of preparation thereof and use thereof
US9176150B2 (en) 2003-01-31 2015-11-03 AbbVie Deutschland GmbH & Co. KG Amyloid beta(1-42) oligomers, derivatives thereof and antibodies thereto, methods of preparation thereof and use thereof
US8497072B2 (en) 2005-11-30 2013-07-30 Abbott Laboratories Amyloid-beta globulomer antibodies
US8691224B2 (en) 2005-11-30 2014-04-08 Abbvie Inc. Anti-Aβ globulomer 5F7 antibodies
US10538581B2 (en) 2005-11-30 2020-01-21 Abbvie Inc. Anti-Aβ globulomer 4D10 antibodies
US10323084B2 (en) 2005-11-30 2019-06-18 Abbvie Inc. Monoclonal antibodies against amyloid beta protein and uses thereof
US10208109B2 (en) 2005-11-30 2019-02-19 Abbvie Inc. Monoclonal antibodies against amyloid beta protein and uses thereof
US9540432B2 (en) 2005-11-30 2017-01-10 AbbVie Deutschland GmbH & Co. KG Anti-Aβ globulomer 7C6 antibodies
US9951125B2 (en) 2006-11-30 2018-04-24 Abbvie Inc. Aβ conformer selective anti-Aβ globulomer monoclonal antibodies
US9394360B2 (en) 2006-11-30 2016-07-19 Abbvie Inc. Aβ conformer selective anti-Aβ globulomer monoclonal antibodies
US9359430B2 (en) 2006-11-30 2016-06-07 Abbvie Inc. Abeta conformer selective anti-Abeta globulomer monoclonal antibodies
US8877190B2 (en) 2006-11-30 2014-11-04 Abbvie Inc. Aβ conformer selective anti-Aβ globulomer monoclonal antibodies
US8895004B2 (en) 2007-02-27 2014-11-25 AbbVie Deutschland GmbH & Co. KG Method for the treatment of amyloidoses
US9822171B2 (en) 2010-04-15 2017-11-21 AbbVie Deutschland GmbH & Co. KG Amyloid-beta binding proteins
US8987419B2 (en) 2010-04-15 2015-03-24 AbbVie Deutschland GmbH & Co. KG Amyloid-beta binding proteins
US10047121B2 (en) 2010-08-14 2018-08-14 AbbVie Deutschland GmbH & Co. KG Amyloid-beta binding proteins
US9062101B2 (en) 2010-08-14 2015-06-23 AbbVie Deutschland GmbH & Co. KG Amyloid-beta binding proteins

Also Published As

Publication number Publication date
JPS5191321A (en) 1976-08-10
PL99599B1 (en) 1978-07-31
ATA981675A (en) 1977-12-15
SU576898A3 (en) 1977-10-15
DE2500076A1 (en) 1976-07-08
ZA758050B (en) 1976-12-29
EG11987A (en) 1981-12-31
DD121875A5 (en) 1976-09-05
IL48766A (en) 1979-11-30
NL7514627A (en) 1976-07-06
DE2500076B2 (en) 1979-02-22
SE7514388L (en) 1976-07-05
CA1058075A (en) 1979-07-10
ES443982A1 (en) 1977-07-16
FR2296429B1 (en) 1978-12-01
AT344883B (en) 1978-08-10
DK144679C (en) 1982-10-11
IE43449B1 (en) 1981-02-25
FR2296429A1 (en) 1976-07-30
SE437470B (en) 1985-03-04
BE837211A (en) 1976-06-30
JPS5512001B2 (en) 1980-03-29
IE43449L (en) 1976-07-02
NL179824B (en) 1986-06-16
IL48766A0 (en) 1976-02-29
IN143525B (en) 1977-12-17
NL179824C (en) 1986-11-17
DE2500076C3 (en) 1982-11-18
DK584375A (en) 1976-07-03
AU505416B2 (en) 1979-11-22
DK144679B (en) 1982-05-10
AU8792175A (en) 1977-07-14

Similar Documents

Publication Publication Date Title
GB1495159A (en) Process reducing the anticomplementary activity of gamma globulins
Chazotte et al. Further studies on F1-ATPase inhibition by local anesthetics
ES8506758A1 (en) An occulusion compound of 2-nitroxymethyl-6-chloropyridine with beta-cyclodextrin and process for preparation thereof.
GB1418849A (en) Production of antisera
GB1473245A (en) Purification of plasminogen
GB779493A (en) Process for the isolation of stable, highly purified gamma globulin preparations
GB1480700A (en) Rifamycin s and sv derivatives
GB1312391A (en) Basically substituted 4 3h- quinazolinone derivatives and process for their manufacture
GB1386150A (en) 6-acylaminophenyl-4,5-dihydropyridazones
GB1528259A (en) Process for the preparation of a gamma-globulin solution suitable for intravenous administration
IE42521L (en) Treating a sodium lauryl sulphate-whey protein complex.
DE3687995D1 (en) METHOD FOR PURIFYING INTERFERON AND COMPOSITION MADE THEREOF.
GB1436529A (en) Process for preparing a blood fraction
GB1469908A (en) Preparation containing an enzyme for removal of anti-complement from gamma globulin
GB1377596A (en) Process for the preparation of 1-substituted 3-hydroxypyrazoles
GB1243953A (en) Benzdiazepine derivatives
GB967594A (en) 2-(2,6-dimethyl-3-hydroxy-4-tert-butyl-benzyl)-2-imidazoline,and acid addition salts thereof,and process for their manufacture
GB1312392A (en) Basically substituted 4 3h-quinazolinone derivatives and process for their manufacture
GB1222294A (en) Oxazinobenzodiazepine derivatives
GB1384684A (en) 1,3,5-triazine and process for the preparation thereof
Lewis et al. Erythropoietic Activity in Human Urine Concentrate.
GB1171827A (en) Improvements in or relating to Substituted Propanols and the Manufacture thereof
GB1285857A (en) Purification of gamma globulin
GB1509445A (en) Benzodiazepine derivatives and a process for the preparation thereof
HUT41632A (en) Process for preparing agents for the enhancement of protein absorption

Legal Events

Date Code Title Description
PS Patent sealed [section 19, patents act 1949]
PE20 Patent expired after termination of 20 years

Effective date: 19951228